ArticleThe American journal of pathology2008
Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.
Article in The American journal of pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 70 citations in OpenAlex.
- A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis.Biology · 2026Review
- HMGB1-Platelet Interactions: Mechanisms and Targeted Therapy Strategies.Thrombosis and haemostasis · 2026Review
- Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders.Pharmaceutics · 2022Article
- Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia (International journal of molecular sciences · 2022Article
- Targeting Inflammation Driven by HMGB1 in Bacterial Keratitis-A Review.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Urocortin Induces Phosphorylation of Distinct Residues of Signal Transducer and Activator of Transcription 3 (STAT3) via Different Signaling Pathways.Medical science monitor basic research · 2019Article
- Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.World journal of gastroenterology · 2017Review
- Sterile Neuroinflammation and Strategies for Therapeutic Intervention.International journal of inflammation · 2017Review
- Adiponectin Inhibits LPS-Induced HMGB1 Release through an AMP Kinase and Heme Oxygenase-1-Dependent Pathway in RAW 264 Macrophage Cells.Mediators of inflammation · 2016Article
- High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.Acta physiologica (Oxford, England) · 2015Review
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.Expert review of clinical immunology · 2014Review
- Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.The Journal of biological chemistry · 2014Article
- Targeting HMGB1 in the treatment of sepsis.Expert opinion on therapeutic targets · 2014Review
- Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.British journal of clinical pharmacology · 2014Review
- Article
- Article
- Protective role of the neuropeptide urocortin II against experimental sepsis and leishmaniasis by direct killing of pathogens.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Originally described as a nuclear protein that bends DNA, the high mobility group box 1 protein (HMGB1) has recently emerged as a necessary and sufficient late mediator of severe sepsis. HMGB1 is therefore a molecular target that provides a wide window for clinical intervention in sepsis. Vasoactive intestinal peptide (VIP) and urocortin are two well known anti-inflammatory neuropeptides that protect against several immune disorders by regulating a wide panel of inflammatory mediators. In this study, we demonstrate the therapeutic effect of VIP and urocortin in various models of established sepsis: both agents reduced lethality induced by cecal ligation and puncture or by injection of live Escherichia coli. The therapeutic effect of VIP and urocortin was accompanied by a decrease in systemic levels of HMGB1. In addition, administration of recombinant HMGB1 completely reversed the protective effect of VIP and urocortin in experimental sepsis. In vitro and ex vivo studies show that both VIP and urocortin down-regulate translocation of HMGB1 from the nucleus to the cytoplasm and its subsequent secretion by activated macrophages, suggesting that macrophages are major targets in the inhibitory activity of these neuropeptides. To our knowledge, VIP and urocortin are the first endogenous inhibitors of HMGB1 secretion shown to improve sepsis survival in a clinically relevant time frame.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.